AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Investors who Lost Money on AstraZeneca PLC (AZN) Should Contact Levi & Korsinsky About Pending Class Action - AZN
NEW YORK, NY / ACCESSWIRE / January 8, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
AZN Investors Have Opportunity to Lead AstraZeneca PLC Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
NEW YORK, NY / ACCESSWIRE / January 8, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca securities between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period").
Shareholders that lost money on AstraZeneca PLC(AZN) should contact Levi & Korsinsky about pending Class Action - AZN
NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Class Action Filed Against AstraZeneca PLC (AZN) Seeking Recovery for Investors - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In AstraZeneca To Contact Him Directly To Discuss Their Options NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered losses exceeding $100,000 in AstraZeneca between between February 23, 2022 and December 17, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN) and reminds investors of the Feb. 21, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 21, 2025 in AstraZeneca PLC Lawsuit - AZN
NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
AstraZeneca (AZN) Reels from China Investigation and Investor Suit– Hagens Berman
SAN FRANCISCO, CA / ACCESSWIRE / January 7, 2025 / AstraZeneca (NASDAQ:AZN), the Anglo-Swedish pharmaceutical giant, has seen its stock price tumble 15 percent over the past six months, buffeted by a series of unsettling reports emanating from China. A widening investigation by China regulators into alleged illegal drug imports, data breaches, and potential health insurance fraud has cast a shadow over the company's prospects in a critical market, triggering a securities class action lawsuit in the United States.
AstraZeneca PLC Class Action: Levi & Korsinsky Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZN
NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
J&J lung cancer treatment extends lives versus AstraZeneca drug
Johnson & Johnson (NYSE:JNJ) has said its chemotherapy-free combination extended lung cancer patients' lives compared to AstraZeneca PLC (LSE:AZN)'s Tagrisso drug in a head-to-head study. The combination showed “clinically meaningful and statistically significant improvement in overall survival” against Astra's blockbuster treatment, a Tuesday statement said.
AstraZeneca pipeline undervalued and underrated, broker suggests
AstraZeneca PLC (LSE:AZN) decline has gone too far, according to the analysts at Berenberg, who note that attention in 2025 switches to the breast cancer, hypertension and obesity pipelines. Currently, the broker says that the shares are trading in line with the value of marketed drugs only, with no value assigned to the pipeline.
J&J's combo extends patients' lives in head-to-head study with AstraZeneca's drug
Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful improvement in extending lives of patients with a type of lung cancer, compared to AstraZeneca's blockbuster drug Tagrisso.
Shareholders of AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights - AZN
NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
